193 related articles for article (PubMed ID: 24285767)
1. Angiotensin-converting enzyme inhibitors for intermittent claudication associated with peripheral arterial disease.
Hunter MR; Cahoon WD; Lowe DK
Ann Pharmacother; 2013 Nov; 47(11):1552-7. PubMed ID: 24285767
[TBL] [Abstract][Full Text] [Related]
2. Effect of ramipril on walking times and quality of life among patients with peripheral artery disease and intermittent claudication: a randomized controlled trial. Journal of the American Medical Association 2013; 309: 453-460.
Kurklinsky AK; Levy M
Vasc Med; 2013 Aug; 18(4):234-6. PubMed ID: 23867841
[TBL] [Abstract][Full Text] [Related]
3. Ramipril for treatment of intermittent claudication.
Poredos P
Vasa; 2013 Jul; 42(4):237-8. PubMed ID: 23823855
[No Abstract] [Full Text] [Related]
4. Do angiotensin converting enzyme inhibitors improve walking distance in patients with symptomatic lower limb arterial disease? A systematic review and meta-analysis of randomised controlled trials.
Shahin Y; Mazari F; Chetter I
Int J Surg; 2011; 9(3):209-13. PubMed ID: 21195215
[TBL] [Abstract][Full Text] [Related]
5. Meta-analysis of angiotensin converting enzyme inhibitors effect on walking ability and ankle brachial pressure index in patients with intermittent claudication.
Shahin Y; Barnes R; Barakat H; Chetter IC
Atherosclerosis; 2013 Dec; 231(2):283-90. PubMed ID: 24267241
[TBL] [Abstract][Full Text] [Related]
6. Effect of ramipril on walking times and quality of life among patients with peripheral artery disease and intermittent claudication: a randomized controlled trial.
Ahimastos AA; Walker PJ; Askew C; Leicht A; Pappas E; Blombery P; Reid CM; Golledge J; Kingwell BA
JAMA; 2013 Feb; 309(5):453-60. PubMed ID: 23385271
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for the prevention of migraines.
Gales BJ; Bailey EK; Reed AN; Gales MA
Ann Pharmacother; 2010 Feb; 44(2):360-6. PubMed ID: 20086184
[TBL] [Abstract][Full Text] [Related]
8. Ramipril improves walking times and quality of life in patients with stable intermittent claudication.
Brittenden J
Evid Based Med; 2014 Feb; 19(1):16. PubMed ID: 23842688
[No Abstract] [Full Text] [Related]
9. PURLs: ramipril for claudication?
Stephens LA; Rogers N; Stevermer JJ
J Fam Pract; 2013 Oct; 62(10):579-80. PubMed ID: 24143348
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
11. Randomized clinical trial of angiotensin-converting enzyme inhibitor, ramipril, in patients with intermittent claudication.
Shahin Y; Cockcroft JR; Chetter IC
Br J Surg; 2013 Aug; 100(9):1154-63. PubMed ID: 23842829
[TBL] [Abstract][Full Text] [Related]
12. The Roles of ACE Inhibitors in Lower Extremity Peripheral Artery Disease.
Barrons RW; Woods JA
Am J Ther; 2016; 23(1):e7-15. PubMed ID: 24786850
[TBL] [Abstract][Full Text] [Related]
13. ACP Journal Club. Ramipril improved walking times and QOL in peripheral artery disease and intermittent claudication.
Jaar BG
Ann Intern Med; 2013 Jun; 158(12):JC7. PubMed ID: 23778931
[No Abstract] [Full Text] [Related]
14. Effect of blood pressure lowering medications on leg ischemia in peripheral artery disease patients: A meta-analysis of randomised controlled trials.
Thomas Manapurathe D; Krishna SM; Dewdney B; Moxon JV; Biros E; Golledge J
PLoS One; 2017; 12(6):e0178713. PubMed ID: 28575088
[TBL] [Abstract][Full Text] [Related]
15. Effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on risk of atrial fibrillation before coronary artery bypass grafting.
Johnston K; Stephens S
Ann Pharmacother; 2012 Sep; 46(9):1239-44. PubMed ID: 22947592
[TBL] [Abstract][Full Text] [Related]
16. Medications for improving walking performance in peripheral artery disease: still miles to go.
McDermott MM
JAMA; 2013 Feb; 309(5):487-8. PubMed ID: 23385276
[No Abstract] [Full Text] [Related]
17. Management of intermittent claudication with pentoxifylline: meta-analysis of randomized controlled trials.
Hood SC; Moher D; Barber GG
CMAJ; 1996 Oct; 155(8):1053-9. PubMed ID: 8873633
[TBL] [Abstract][Full Text] [Related]
18. Renin-angiotensin system mediators and Raynaud's phenomenon.
Wood HM; Ernst ME
Ann Pharmacother; 2006 Nov; 40(11):1998-2002. PubMed ID: 17003081
[TBL] [Abstract][Full Text] [Related]
19. Potential vascular mechanisms of ramipril induced increases in walking ability in patients with intermittent claudication.
Ahimastos AA; Latouche C; Natoli AK; Reddy-luthmoodoo M; Golledge J; Kingwell BA
Circ Res; 2014 Mar; 114(7):1144-55. PubMed ID: 24397981
[TBL] [Abstract][Full Text] [Related]
20. Asymptomatic peripheral arterial disease: is pharmacological prevention of cardiovascular risk cost-effective?
Sigvant B; Henriksson M; Lundin F; Wahlberg E
Eur J Cardiovasc Prev Rehabil; 2011 Apr; 18(2):254-61. PubMed ID: 21450673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
